CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 31, 2019	Apr. 01, 2018
Income Statement [Abstract]
Revenues	[1]	$ 13,118	$ 12,906
Costs and expenses:
Cost of sales	[1],[2]	2,433	2,563
Selling, informational and administrative expenses	[1],[2]	3,339	3,412
Research and development expenses	[1],[2]	1,703	1,743
Amortization of intangible assets	[1]	1,183	1,196
Restructuring charges and certain acquisition-related costs	[1]	46	43
Other (income)/deductions––net	[1]	92	(178)
Income from continuing operations before provision for taxes on income	[1],[3]	4,323	4,127
Provision for taxes on income	[1]	433	556
Income from continuing operations	[1]	3,889	3,571
Discontinued operations––net of tax	[1]	0	(1)
Net income before allocation to noncontrolling interests	[1],[4],[5],[6]	3,889	3,570
Less: Net income attributable to noncontrolling interests	[1]	6	9
Net income attributable to Pfizer Inc.	[1]	$ 3,884	$ 3,561
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.69	$ 0.60
Discontinued operations––net of tax (in dollars per share)	[1]	0.00	0.00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.69	0.60
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	0.68	0.59
Discontinued operations––net of tax (in dollars per share)	[1]	0.00	0.00
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1]	$ 0.68	$ 0.59
Weighted-average shares––basic	[1]	5,635	5,957
Weighted-average shares––diluted	[1]	5,750	6,057

[1] Amounts may not add due to rounding.

[2] Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.

[3] Income from continuing operations before provision for taxes on income. Biopharma’s earnings include dividend income of $64 million in the first quarter of 2019 and $59 million in the first quarter of 2018 from our investment in ViiV. For additional information, see Note 4.

[4] Amounts may not add due to rounding.

[5] Amounts may not add due to rounding.

[6] Amounts may not add due to rounding.